Healthcare Alternative Data: Signal + HIPAA Bounds

Healthcare-related alternative data sits in the tightest regulatory frame of any vertical on the catalog. Claims flowing through covered entities are HIPAA-covered; device-level mobility to named clinics is an enforcement-shaped third rail after FTC location orders; consumer-app health data often falls under the expanded FTC Health Breach Notification Rule. Operator-grade buyers still extract signal when compliance is the scaffolding. Start at Healthcare industry hub, Alternative Data for Finance, and healthcare privacy-safe signals. Public claims should match contracted lanes — see AI search readiness.

Definition: operator-grade healthcare alternative data

Operator-grade healthcare alternative data is commercial signal where each SKU maps to an explicit compliance frame — HIPAA Safe Harbor or Expert Determination for claims-adjacent feeds, aggregate cohort mobility for care-category utilization, or consented survey panels governed by FTC HBNR — without conflating lanes or resolving devices to named clinics.

Where Healthcare Alt-Data Signal Lives: Three Lanes

• Claims-adjacent, de-identified — procurement patterns, pharmacy timing, encounter mixes under Safe Harbor or Expert Determination.
• Aggregated mobility-to-care-category — metro or cohort utilization without device resolution to named clinics.
• Consented survey and sentiment panels — condition-level adherence and switching intent from first-party enrollment.

A buyer sourcing all three lanes gets a compound view — claims-adjacent shows what was prescribed and procured, mobility aggregates show where utilization shifts at population level, and survey panels show adherence, side effects, and switching intent. Any one lane alone is partial; the stack is where analytics work gets done. Conflating lanes is the most common procurement mistake. Document which lane each model consumes before seed match testing.

The diagnostic question for every SKU: what compliance frame applies at origin, and does de-identification or aggregation move the feed to a frame where your intended use is allowed? Treat that question as mandatory per SKU, not once per vendor.

1. If data originates from a covered entity or business associate, it is HIPAA-covered until de-identified under Safe Harbor or Expert Determination — Data-Use Agreements must reflect that chain.
2. If data originates from consumer apps not affiliated with a covered entity, it is not HIPAA-covered but often falls under FTC HBNR and state privacy laws.
3. If data is mobility showing devices at medical facilities at device level, it is not HIPAA-covered but is not safe to license post-2024 FTC orders.
4. If data is aggregated to metro or cohort care-category analytics without person-level resolution, it typically sits outside HIPAA, HBNR identifiable health information scope, and FTC sensitive-category sale prohibitions for device traces.

What HIPAA Actually Covers — And What It Doesn't

HIPAA Privacy Rule applies to PHI held by or flowing through covered entities and business associates. It does not automatically cover fitness trackers, symptom checkers, or period apps with no covered-entity affiliation — that gap is partly closed by FTC HBNR and state laws. Ask every vendor: what frame applies at origin, and does de-identification or aggregation move the SKU to a frame that matches your use case?

The FTC HBNR 2024 Update: Non-HIPAA Health Data Got Rules

The expanded HBNR covers a broader class of apps and services accessing consumer health information — including many not affiliated with covered entities. Breach includes unauthorized disclosure and sale without adequate consent. Vendors must document source-app policies and that alt-data sale is covered by collection-time consent. Pair diligence with data brokers post-FTC orders and geo-panel audit 2026 for mobility context.

Mobility Aggregated Is the Line; Device-Level Is Not

Usable mobility signal is metro-level or cohort-level — urgent-care utilization by DMA, retail-clinic trends by trade area. Unusable signal resolves a device to a named clinic visit. Top-tier vendors scrub sensitive venues before egress; buyers should request scrubbing category lists and QA results. Global Mobility programs still require privacy-safe location controls when joined to any activation use case.

Building a Compliant Healthcare Alt-Data Program

1. Lane-one DUAs for claims-adjacent feeds with de-ID attestation.
2. Lane-two contracts forbidding device-level visit resolution; document scrubbing.
3. Lane-three panel consent frameworks with HBNR attestation where applicable.
4. Cross-lane analytics at aggregate grain; clean rooms for richer joins under narrowest frame.
5. Annual re-attestation when vendors add sources or geographies.

Life-sciences, payer, and investor buyers who document lanes upfront get procurement dynamics, utilization trends, and patient sentiment without inherited exposure from mis-framed SKUs. Clean room joins support richer joins when each party's permitted use stays compatible. Adjacent MAID Feed or Global Mobility programs still require separate lane diligence — HIPAA bounds on claims data do not automatically bless device-level programs.

Investor and payer teams should keep public methodology aligned with contracted lanes — conflicting web copy becomes AI diligence noise. FAQ schema patterns and AI search readiness help models quote accurate definitions when legal approves visible Q&A.

Scope POI data for care-category venue typing when mobility joins place catalogs — polygon quality still matters for category rollups even without device-level clinic resolution.

Procurement questions to ask every healthcare SKU

• What compliance frame applies at collection — covered entity, consumer app, or aggregate mobility?
• Which de-identification method is documented — Safe Harbor, Expert Determination, or not applicable?
• Can the vendor produce scrubbing QA on sensitive POI categories aligned to FTC orders?
• Does the contract forbid device-level resolution to named clinics for activation exports?
• How do deletion and opt-out signals propagate to your licensed copy?

Life-sciences, payer, and investor buyers who document answers in the RFP appendix close faster than teams debating lanes verbally in week four. Cross-link diligence to state broker registration when vendors qualify as brokers and to clean room joins when richer joins are needed without commingling compliance frames.

Payer analytics teams should pre-register which lane feeds each dashboard — mixing claims-adjacent fields with survey sentiment without documentation invites audit questions when outputs influence network decisions.

Investor relations copy on healthcare alt-data should cite the same lane boundaries legal approved — models and procurement bots read AI search readiness and FAQ blocks together.

When mobility joins care-category POI, require polygon refresh and sensitive scrubbing evidence in the same packet — place catalogs are not PHI, but visit construction can be.

Life-sciences and payer buyers should keep lane-specific definitions in RFP appendices so legal, data science, and public marketing do not diverge — AI search readiness for B2B data sites describes how to keep Dataset schema and visible copy aligned for diligence bots.

Build an internal link path from this resource to relevant products pages and AI search readiness for B2B data sites within two hops — models and procurement agents use that graph to validate public claims against pilot evidence.